Erythropoietin

Links to news articles on Erythropoietin .

Stada says Jan, Feb sales up 22 pct; sees earnings growth ... -- 30 Mar 2006
Turning to products, Stada said it now expects to file for approval of Erythropoietin, to treat anaemia induced by cancer treatment, in the second quarter this ... Forbes

UCI: Doctor leaked Lance documents -- 30 Mar 2006
Tour showed "indisputable" traces of the illegal blood-booster erythropoietin (EPO ... an authorization to use any drugs after he successfully fought his cancer.". People's Daily Online,

Weekly Erythropoietin Not Necessary for Patients with Cancer ... -- Mar 28, 2006
NEW YORK MAR 27, 2006 (Reuters Health) - As a treatment for cancer-related anemia, after initial dosing, an extra large dose of erythropoietin can be given ... Cancerpage.com,

ProMetic Announces Year-End 2005 Financial Results -- Mar 28, 2006
...targets chemotherapy and/or cancer induced anemia stems from a mechanism of action which is different from the current anemia treatment, erythropoietin (EPO). ... Genetic Engineering News,

TODAY ON PHARMALIVE.COM -- Mar 27, 2006
National Comprehensive Cancer Network(R) (NCCN) guidelines for "Cancer and Treatment ... the development of Epoetin alfa, a recombinant erythropoietin (a protein ... PharmaLive.com (press release),

British body rejects EPO drugs for cancer patients -- Mar 17, 2006
...medicines watchdog ruled on Friday that costly erythropoietin (EPO) drugs should not be used to treat anaemia caused by anti-cancer therapy, dealing a blow to ... Reuters

Dacogen™ Improves Outcomes in Myelodysplastic Syndromes -- Mar 15, 2006
2] This study appeared in an early online publication in Cancer on March 10 ... were available to one where the supportive growth factors erythropoietin (EPO) and ... Cancer Consultants (press release),

Amgen's Phase 3 RED-HF(TM) Trial Will Evaluate The Clinical Effect ... -- Mar 19, 2006
If anti-erythropoietin antibody-associated anemia is suspected, Aranesp and other ... of people around the world in the fight against cancer, kidney disease ... Medical News Today (press release),

Skeletal muscle dysfunction in chronic renal failure: effects of ... -- Mar 9, 2006
Studies performed before the advent of recombinant erythropoietin have shown significant ... IL-6-like cytokines and cancer cachexia :consequences of chronic ... AJP-Renal Physiology

Fayette residents hear about bloodless medicine -- Mar 18, 2006
...a reaction, quicker recovery, lower costs and lower risks of cancer. ... Another technique, Erythropoietin, involves a synthetic hormone, Procit, that stimulates ... Uniontown Herald Standard,

More doping allegations for Armstrong -- Feb 27, 2006
Tour showed "indisputable" traces of the illegal blood-boosting erythropoietin (EPO). ... any medicine in relation with possible consequences of the cancer he had ... Stuff.co.nz,

IT as Pharma Growth Tonic -- Feb 28, 2006
Similarly, we introduced Wepox, a recombinant erythropoietin used to treat anaemia caused by cancer and chronic renal failure, about four years ago. ... Bio-IT World,

New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) ... -- Mar 13, 2006
...the treatment of anemia with the development ofrecombinant erythropoietin, Epoetin alfa. ... of people around the world in the fight against cancer,kidney disease ... Finanzen.net,

Cervical cancer work recognised -- 25 Jan 2006
...a major role in the purification and characterisation of erythropoietin, a hormone ... provided a therapy for severe anaemia in kidney failure cases and cancer. ... Bangkok Post,

Cancer patients likely to be denied fatigue treatment -- Jan 22, 2006
...primary care trusts do not pay for erythropoietin (EPO), a hormone used to treat breathlessness and reduced energy levels. Most people with cancer suffer a ... Telegraph.co.uk,

Scared of vampires? No, it's anaemia that should worry us -- Jan 23, 2006
The alternative is erythropoietin (EPO) — a hormone that boosts the production of red ... As a result, our cancer patients suffer not only more physical symptoms ... Times Online,

Amgen Seen Taking EPO Share From J&J -- Jan 23, 2006
...neutral" rating on Amgen (nasdaq: AMGN - news - people ), citing potential market-share gains for the company's Erythropoietin (EPO) product line for cancer. ... Forbes

Increase ribavirin dose for better HCV treatment response in ... -- Jan 18, 2006
...can authorise its use throughout the UK, concluded that "erythropoietin is not recommended for the treatment of anaemia induced by cancer treatment except in ... Aidsmap,

Oncologist warns of cancer-related anaemia -- Jan 13, 2006
...with anaemia, lowering the performance of cancer patients and their ability to carry out everyday tasks. However, injections of erythropoietin (EPO) can ... Irish Medical News,

Computer Modeling Suggests Cost-Effectiveness of Once Weekly ... -- Jan 13, 2006
Human recombinant erythropoietin (rHuEPO) can enhance red blood cell production in patients ... Although studies in patients with lung cancer have documented the ... Cancer Consultants (press release),

16 teams set for Calif. cycling event -- Jan 18, 2006
...is the world's leading producer of synthetic versions of a hormone called erythropoietin or EPO. The drug, intended for kidney and cancer patients, has been ... CNN/SI

Empiricus: our clinical journal commentator -- Jan 17, 2006
Anaemia in older patients having chemotherapy for lung cancer is directly ... In a consecutive series of Italian cases, erythropoietin successfully restored ... AustralianDoctor.com (subscription),

Copycat Cures -- Jan 10, 2006
...radicals, and it could eventually be used to treat cancer, arthritis, pain ... CA's Affymax each say they have developed mimetics of erythropoietin, biotech's best ... MIT Technology Review,

Lipoxen plc lists on AIM raising £3.78million -- Jan 17, 2006
...costs for patients being treated for kidney failure, hepatitis C and cancer. ... These products include current blockbusters erythropoietin (EPO), paclitaxel and a ... Biotech Intelligence (press release),

European drugmakers, Pfizer stoke pharma stocks -- Jan 4, 2006
...study also found Merck's (MRK) anti-cholesterol drug Zocor did not cause cancer. ... its NE-180 drug candidate, a long-acting version of erythropoietin, a widely ... Investor's Business Daily (subscription)

A Number of High Value Drugs due to Come off Patent in the USA and ... -- Jan 6, 2006
...have attracted generic competition, such as cancer therapies carboplatin ... older high value biopharmaceuticals, including erythropoietin, filgrastim, recombinant ... Genetic Engineering News,

Amgen's blockbuster anemia drugs facing patent challenge -- Dec 24, 2005
...other, are used primarily to treat the anemia caused by cancer chemotherapy and ... scientists, Fu-Kuen Lin, who isolated the human gene for erythropoietin, or EPO ... Providence Journal (subscription),

Pound - cycling's Armstrong faces further doping investigations -- Dec 22, 2005
...alleging Armstrong had taken the banned blood booster EPO (erythropoietin) in 1999 ... Armstrong, who overcame testicular cancer to become the most successful rider ... Reuters South Africa,

Armstrong drug probe is on -- 23 Dec 2005
...alleging Armstrong had taken the banned blood booster EPO (erythropoietin) in 1999 ... Armstrong, who overcame testicular cancer to become the most successful rider ... The Mercury (subscription),

A Biotech Battle Royal -- 23 Dec 2005
...other, are used primarily to treat the anemia caused by cancer chemotherapy and ... scientists, Fu-Kuen Lin, who isolated the human gene for erythropoietin, or EPO ... New York Times,

Ads for Drugs to Treat Cancer-Related Fatigue May Be Misleading ... -- Dec 16, 2005
Direct-to-consumer advertising promoting the use of erythropoietin to alleviate cancer-related fatigue fails to point out that the drug is only effective ... Genetic Engineering News,

Ads for Drugs to Treat Cancer-Related Fatigue May Be Misleading ... -- Dec 16, 2005
NEW ROCHELLE, NY--(BUSINESS WIRE)--Dec 16, 2005 - Direct-to-consumer advertising promoting the use of erythropoietin to alleviate cancer-related fatigue fails ... PharmaLive.com (press release),

Roche Announces Successful Completion of Four Pivotal Phase III ... -- Dec 16, 2005
...which will be the first - and only - continuous erythropoietin receptor activator. ... in diagnostics, the leading supplier of pharmaceuticals for cancer, as well ... PR Newswire (press release),

Benefits Of Aranesp Dosed Every Three Weeks For Chemotherapy ... -- Dec 12, 2005
National Comprehensive Cancer Network® (NCCN) guidelines for "Cancer and Treatment ... treatment with the development of recombinant erythropoietin, Epoetin alfa. ... Medical News Today (press release),

TODAY ON PHARMALIVE.COM -- Dec 12, 2005
Comprehensive Cancer Network(R) (NCCN) guidelines for "Cancer and Treatment ... anemia treatment with the development of recombinant erythropoietin, Epoetin alfa. ... PharmaLive.com (press release),

Hematide(TM) Shown in Phase 2 Trial to Stimulate Red Blood Cell ... -- Dec 12, 2005
...previously with erythropoietin. Affymax anticipates initiating a Phase 2 dose-finding trial of Hematide for treatment of anemia in cancer patients later this ... PR Newswire (press release),

Witch-hunt' persuades angry Armstrong -- Dec 18, 2005
...he had tested positive seven times for the blood-booster erythropoietin during the first of his Tour wins, in 1999. Armstrong, a cancer survivor, reiterated ... Guardian Unlimited,

Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in ... -- Dec 11, 2005
PRCA and the patient evaluated for the presence of antibodies to erythropoietin products. ... of people around the world in the fight against cancer, kidney disease ... Business Wire (press release),

REVLIMID(R) Clinical Results as Oral Treatment Regimen in ... -- Dec 13, 2005
Cortez, MD, of the University of Texas, MD Anderson Cancer Center, Houston ... patients (27%), ten anagrelide patients (24%), and six erythropoietin patients (15%). ... Yahoo! News (press release)

ProMetic Reports Positive Results for Phase 1 Trial of PBI-1402 -- Dec 12, 2005
...than the current drug of choice for the treatment of anemia, erythropoietin (EPO). ... The first clinical trial to take place in cancer patients will consist of a ... CCNMatthews (Communiqués de presse),

Aranesp: pure red cell aplasia and severe anemia associated with ... -- Dec 4, 2005
...in 59 ( 4% ) of CRF patients and 36 ( 3% )of cancer patients ... antibodies capable of neutralizing the activity of Aranesp or endogenous erythropoietin at baseline ... Xagena.it,

American, German scientists win Prince Mahidol Awards -- Nov 30, 2005
...a major role in the purification and characterization of erythropoietin, an effective therapy for severe anemia in kidney failure and cancer patients worldwide ... Bangkok Post,

Efficacy of Revlimid in patients with myelofibrosis -- Dec 13, 2005
Cortez, of the University of Texas, MD Anderson Cancer Center, Houston ... patients ( 27% ), ten Anagrelide patients ( 24% ), and six Erythropoietin patients ( 15 ... Xagena.it,

Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... -- Dec 7, 2005
...have evolved from a group of diseases for which no treatment options were available to one in which the supportive growth factors erythropoietin (EPO) and ... Cancer Consultants (press release),

Cycling: Inagural Tour of California Will Feature World's Top ... -- Nov 23, 2005
Based in Thousand Oaks, Amgen develops medicines, including erythropoietin (EPO), for the treatment of cancer, kidney disease and other serious illnesses. ... RunnersWeb,

First Long Term Phase II Study of CERA in Renal Patients Not Yet ... -- Nov 13, 2005
...leading medicines in therapeutic areas including cancer, HIV/AIDS ... Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) Maintains Hemoglobin levels ... PR Newswire (press release),

DNAPrint Genomics and SeraCare's Genomics Collaborative Combine to ... -- Nov 14, 2005
...responded to a standard carboplatin/tamoxifen regimen for breast cancer with those ... theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein ... Market Wire (press release)

FibroGen Provides Update on the Development of FG-2216 and FG-4592 ... -- Nov 13, 2005
...results demonstrate that patients not previously treated with recombinant erythropoietin (EPO) therapy ... Tumor Progression Studies/Anemia of Cancer Models: In ... Business Wire (press release),

Feeling tired? Why anaemia could be the culprit -- Nov 9, 2005
Now we have erythropoietin (EPO). ... Once the patient’s haemoglobin has increased, so are the almost universal symptoms of cancer alleviated for a time. ... Times Online,

Stada 9-mths profit sharply higher; reiterates FY guidance UPDATE -- Nov 10, 2005
...for cancer therapy, the most promising being the autologous tumour vaccine Reniale and Erythropoietin, which is used to treat anemia induced by cancer treatment ... Forbes

Affymax Presents Hematide(TM) Preclinical Data At American Society ... -- Nov 11, 2005
...not on dialysis and have not been treated previously with erythropoietin is underway ... finding trial of Hematide for treatment of anemia in cancer patients later ... PR Newswire (press release),

Switching to NeoRecormon Improves Anaemia Management and Provides ... -- Nov 10, 2005
Roche is developing the first Continuous Erythropoietin Receptor Activator (CERA) for global commercialisation in renal- and cancer-related anaemia. ... PR Newswire UK (press release),

Bresagen to Expand Into Mammalian Cell-derived Products -- Nov 8, 2005
...products include major drugs such as Epogen® (recombinant erythropoietin) and Enbrel ... of its oncolytic virus technology ie viruses for the treatment of cancer. ... PharmaLive.com (press release),

New Survey Shows Cancer Patients Continue to Suffer From Extreme ... -- Oct 31, 2005
...leukaemia (haematological tumours), who have a relative erythropoietin deficiency and are ... the leading supplier of medicines for cancer and transplantation and ... PR Newswire UK (press release),

Amgen Files Lawsuit Against Roche for Patent Infringement -- Nov 9, 2005
Amgen's patent rights on erythropoietin protect Amgen's breakthrough inventions. ... millions of people around the world in the fight against cancer, kidney disease ... Genetic Engineering News,

Amgen sues rival for patent violations -- Nov 10, 2005
Roche is in its final phase of large studies of CERA, or "Continuous Erythropoietin Receptor Activator ... Longer-lasting Aranesp treats dialysis and cancer patients ... Ventura County Star (subscription),

Data Show Aranesp(R) (Darbepoetin Alfa) Administered Once Monthly ... -- Nov 12, 2005
...based erythopoiesis stimulating agents (ESAs), including endogenous erythropoietin, Aranesp stimulates ... the world in the fight against cancer, kidney disease ... Genetic Engineering News,

Data Show Aranesp(R) (Darbepoetin Alfa) Administered Once Monthly ... -- Nov 12, 2005
...anemia treatment with the development of a recombinanthuman erythropoietin, epoetin alfa ... of people around the world in the fight against cancer,kidney disease ... Finanzen.net,

Aranesp® Does Not Increase Relapses in Patients with Lung Cancer ... -- Oct 19, 2005
...there has been concern about the potential for erythropoietins to increase relapse rates due to the presence of erythropoietin receptors on some cancer cells. ... Cancer Consultants (press release),

Amgen sues Roche over Epogen patents -- Nov 9, 2005
...preventing the manufacturing or sale of recombinant human erythropoietin, including "pegylated ... patients as well as for anemia in cancer patients undergoing ... Reuters

Drug confessions: Cycling is dope -- Nov 9, 2005
The test showed evidence of recombinant erythropoietin (rEPO), a prohibited drug as ... said the drug was originally borne from kidney and cancer technology but ... Excalibur Online,

Endocrinology & Metabolism News, October 2005 -- Oct 21, 2005
Based on these findings, erythropoietin appears to play an independent role as an ... hot flashes in women receiving systemic therapy for breast cancer in a ... Journal of Clinical Endocrinology and Metabolism,

Bike race coming to Monterey -- Nov 3, 2005
Based in Thousand Oaks, Amgen develops medicines, including erythropoietin, for the treatment of cancer, kidney disease and other serious illnesses. ... Monterey County Herald,

DNAPrint Genomics Acquires Kenna Technologies -- Nov 1, 2005
...team will support the clinical development of DNAPrint's PT-401 Super EPO erythropoietin dimer for ... These pathways are common targets of current cancer therapies ... Market Wire (press release)

EPO pioneer to sponsor race -- Nov 2, 2005
...the news that the world's biggest producer of EPO (erythropoietin) - arguably cycling's ... Originally created to help people with cancer or kidney problems, its ... TVNZ,

Amgen to Sponsor Tour of California Cycling Race -- Nov 2, 2005
Amgen's anemia drugs, synthetic versions of a hormone called erythropoietin, are meant for people with kidney disease or cancer, but are used by athletes to ... Los Angeles Times,

EPO company to sponsor road race -- Nov 3, 2005
...of anemia drugs, synthetic versions of a hormone called erythropoietin, or EPO. This drug is meant to help people with kidney disease or cancer but has been ... Australian,

EPO company to sponsor road race -- Nov 3, 2005
...leading producer of anaemia drugs, synthetic versions of a hormone called erythropoietin, (EPO). This drug helps people with kidney disease or cancer but has ... FOX SPORTS,

EPO maker to sponsor cycling race -- Nov 4, 2005
...the February race to fight the perception that EPO (erythropoietin) was created ... making of EPO, arguably cycling's most abused drug, to help cancer and kidney ... ABC Online,

EPO maker to sponsor big race -- Nov 4, 2005
Erythropoietin has been the controversial problem drug for nearly two decades. ... in patients suffering from such ailments as anaemia, kidney disease and cancer. ... Sydney Morning Herald (subscription),

The Insider - November 3 -- Nov 2, 2005
...is to be sponsored by the world’s biggest producer of erythropoietin (EPO). ... to draw attention to the misuse of a product intended to treat cancer and kidney ... Times Online,

The Land of Milk and Money -- Oct 23, 2005
For decades, the scientists who created recombinant erythropoietin to rejuvenate red blood cells and monoclonal antibodies to combat cancer have sought out ... Scientific American

Marin gets major cycling race -- Nov 3, 2005
...biotech firm that pioneered the manufacture of recombinant Erythropoietin, or EPO ... Amgen's medicines were designed to help patients fight cancer, kidney disease ... Marin Independent-Journal,

Abnormal Hemoglobin Levels Linked to Increased Mortality in ... -- Oct 25, 2005
...is often caused by conditions such as chronic renal insufficiency, cancer or bone ... correction of anemia in the elderly with recombinant erythropoietin can slow ... Medscape (subscription)

More information on Erythropoietin from the National Cancer Institute

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:

Stop or slow the growth of cancer cells.
Make it easier for your immune system to destroy, or get rid of, cancer cells.
Keep cancer from spreading to other parts of your body.